GALECTIN-1 EXPRESSION BY 4T1 MAMMARY TUMORS CONTROLS DEVELOPMENT AND ACTIVATION OF B CELLS

VERÓNICA MARTINEZ ALLO, ; ROSA M. MORALES, ; FLORENCIA MOSES, ; GABRIEL A. RABINOVICH, ; MONTANA N. MANSELLE COCCO, ; MARIANA SALATINO, ; NICOLÁS SARBIA, ; SABRINA GATTO, ; TOMÁS D´ALOTTO-MORENO, .; MARTA A. TOSCANO

Mar del plata

Congreso; LXI Reunión Científica de la Sociedad Argentina de Biología (SAIC); LXIV Reunión Anual de la Sociedad Argentina de Inmunología (SAI) y XLVIII Reunión Anual de la Sociedad Argentina de Farmacología Experimental (SAFE); 2016

SAIC, SAI, SAFE

Galectin-1 (Gal1) is an endogenous lectin capable of silencing immune responses and blunting anti-tumor immunity. Since Gal1has been involved in shaping the B cell compartment and the role of these cells in cancer is not fully understood, we sought to understand the role of tumor-derived Gal1 on B cell development and activation. For this, we used the 4T1 murine breast cancer model, which recapitulates human metastatic disease and expresses high amounts of Gal1. As expected, targeted disruption of Gal1 expression in 4T1 cells (shRNA, 4T1 KD) reduced tumor growth and the number of lung metastases (p